The research team led by Alexander Eggermont, MD, PhD, of the Gustave Roussy Cancer Campus Grand Paris, found that among over 1,000 stage III patients with melanoma treated with pembrolizumab in the KEYNOTE-054 study, patients who had an immune-related adverse event (irAE) actually had better outcomes than those without these irAEs, including longer recurrence-free survival. Previously reported data from the main analysis of the study showed that adjuvant therapy with pembrolizumab for patients with resected high-risk melanoma resulted in an 18-month recurrence-free survival of 71.4%, as compared with 53.2% for the placebo group.

Learn more by clicking here.